An innovative platform for cost-effective decentralized manufacturing

Mathias Garny, General Manager
Traditional vaccine manufacturing models rely on scale, which will not directly apply to decentralized/regional manufacture.

Impact of scale on process economics

1) Generic adenovirus process is stainless steel STR, 1E14vp/L, 40% DSP yield, 1E11vp/dose

Cost effectiveness through scale

- Facility
- Materials
- Labour
- CAPEX

1 million doses
USD 10 m
USD 100 m
<USD 1

1 million doses
USD 10'000
USD 100 m
<USD 1

1) Generic adenovirus process is stainless steel STR, 1E14vp/L, 40% DSP yield, 1E11vp/dose
An innovative vaccine manufacturing technology combining process intensification to reduce volumes and integration of multiple unit steps into a single platform.
A technology platform specifically designed to address the CAPEX barrier and achieve cost-effective production in a context of local/regional manufacturing.

**Increased cell concentration and productivity** delivering millions of doses

**Reduced COGS** (lower operational volumes, manual operations)

**Reduced facility CAPEX** with lower cleanroom footprint

**Doses/year** in NevoLine / scale-X nitro 600m²

<table>
<thead>
<tr>
<th></th>
<th>Vero</th>
<th>rVSV-LASV</th>
<th>684 million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MRC-5</td>
<td>Rubella</td>
<td>300 million</td>
</tr>
<tr>
<td></td>
<td>Vero</td>
<td>sIPV</td>
<td>&gt;10 million</td>
</tr>
<tr>
<td></td>
<td>Vero</td>
<td>VSV-Ebola</td>
<td>&gt;6 million</td>
</tr>
</tbody>
</table>

©2023 Univercells Technologies. All Rights Reserved.
Thank you for your attention
www.univercellstech.com

The next evolution of biomanufacturing

Univercells is a trademark or registered trademark of Univercells S.A., exclusively licensed to Univercells Technologies S.A.. Univercells Technologies, the Univercells Technologies logo, scale-X, NevoLine are trademarks or registered trademarks of Univercells Technologies. All other trademarks are the property of their respective owners.